Compositions for allogeneic cell therapy

Patent Number: 7,435,592

This patent covers a composition of activated T cells, either autologous or allogeneic.  It is very interesting since the way the claims issued, it covers pretty much any T cell that has been activated by ligation of CD3 and CD28 (the most common way of activating T cell cells). 

The first independent claim covers a composition of T cells that are contacted with antibodies to CD3 and CD28 and said antibodies are crosslinked by particles that are biodegradable and the composition of the T cells, antibodies, and particles are in an infusion media, with the concentration of cells being at least 10 million cells per ml.

The second independent claim is pretty much the same except it is not limited to only T cells...it is a "treatment effective amount of a population of cells"  

The third independent claim is "A composition of allogeneic T-cells activated with anti-CD3 and anti-CD28 mAbs wherein the T-cells are cross-linked to biodegradable particles coated with an agent reactive against said mAbs for enhanced cytokine and surface molecule expression prior to infusion into a patient, wherein the T-cells are suspended in infusion media at a concentration of at least 10.sup.7 cells or ml of the infusion media" and the forth is "A composition comprising a treatment effective amount of a population of cells, of which at least a portion are T-cells, and whereby said T-cells are labeled with an activating effective amount of one or more monoclonal antibodies, or portions thereof, and a cross-linking effective amount of an agent reactive against said monoclonal antibodies, wherein the T-cells are activated for enhanced cytokine and surface molecule expression prior to infusion into a patient in an infusion media at a concentration of at least 10.sup.7 cells per ml of the infusion media. "

This patent could be very useful for many situations, especially since anti-CD3 and anti-CD28 antibodies are commercially available that are clinical grade.

A composition of T-cells coated with anti-CD3 and anti-CD28 mAbs wherein the anti-CD3 and anti-CD28 are cross-linked by biodegradable particles coated with an agent reactive against said mAbs, and wherein said activated T-cells are suspended in an infusion media suitable for intravenous infusion at a concentration of at least 10.sup.7 cells per ml of the infusion media. 
 

View this patent on the USPTO website.